Eosinophilic Gastritis

Benralizumab induced histological remission at 12 weeks in more than three-fourths of patients with eosinophilic gastritis, although other biomarkers of disease persisted, according to data in The Lancet Gastroenterology & Hepatology.

Treatment with benralizumab induced histological remission, defined as an absence of tissue eosinophilia, among patients with eosinophilic gastritis, according to a study published in The Lancet Gastroenterology & Hepatology.

Lirentelimab was safe and effective in the long-term treatment of patients with eosinophilic gastritis and/or eosinophilic duodenitis, according to a presentation at UEG Week.

A food allergy free diet may effectively improve histologic, molecular, endoscopic and symptomatic disease activity in adult patients with eosinophilic gastritis/gastroenteritis, according to data from Digestive Disease Week.

SAN ANTONIO — A novel therapeutic agent helped reduce eosinophil counts and improve symptoms in patients with eosinophilic gastritis and eosinophilic gastroenteritis, according to study results presented at the American College of Gastroenterology Annual Meeting.